| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥24297.2B | ¥23275.2B | - |
| Operating Income | ¥2484.5B | ¥2232.8B | - |
| Profit Before Tax | ¥2621.9B | ¥2371.5B | - |
| Net Income | ¥1933.8B | ¥1815.4B | - |
| ROE | 5.2% | 5.4% | - |
FY2026 Q3 consolidated results reported revenue of 24,297.2 billion yen (YoY +4.4%), operating income of 2,484.5 billion yen (+11.3%), ordinary income of 2,621.9 billion yen, and net income of 1,933.8 billion yen (+6.5%). Revenue growth remained steady with top-line momentum continuing from prior periods. Operating income growth significantly outpaced revenue growth at 11.3%, indicating improved operating profitability. Pre-tax profit and net income both increased year-over-year, with net income advancing from 1,815.4 billion yen in the prior year period. Total assets reached 58,830.9 billion yen, up 6,331.8 billion yen (+12.1%) year-over-year, while total equity increased to 37,249.7 billion yen from 33,526.8 billion yen (+11.1%). The company maintains full-year forecasts of revenue 3,300.0 billion yen, operating income 335.0 billion yen, and net income 264.5 billion yen with year-end dividend of 35 yen per share.
[Profitability] ROE of 5.2% reflects net profit margin of 8.0%, asset turnover of 0.413, and financial leverage of 1.58x. Operating margin expanded to 10.2% for the nine-month period, improving from 9.5% in FY2024, demonstrating enhanced operating efficiency. Net profit margin of 8.0% remains consistent with the 8.1% recorded in FY2024. DuPont 5-factor decomposition shows tax burden coefficient of 0.738, interest burden coefficient of 1.055 indicating relatively modest interest expense, and EBIT margin of 10.2% reflecting core business profitability. The primary driver of profitability improvement is operating margin expansion, as operating income growth of 11.3% substantially exceeded revenue growth of 4.4%, suggesting improved product mix, cost management, or increased contribution from higher-value segments such as medical and advanced materials. However, ROIC of 4.7% remains below target levels of 7-8%, indicating room for improvement in invested capital efficiency. [Financial Health] Equity ratio stands at 63.2%, reflecting a conservative capital structure and strong financial foundation. The interest burden coefficient of 1.055 suggests limited interest expense burden relative to operating profitability. Total assets increased 12.1% year-over-year to 58,830.9 billion yen, while equity grew 11.1% to 37,249.7 billion yen, with retained earnings accumulation likely contributing to capital expansion. [Investment Efficiency] Asset turnover of 0.413 indicates the company generates 0.41 yen of revenue per yen of assets. [Dividend Policy] Interim dividend of 30 yen and year-end dividend of 35 yen result in annual dividend of 65 yen per share. The calculated payout ratio of 41.8% suggests dividend sustainability under current earnings levels, remaining well below the 60% threshold typically considered sustainable.
Cash and deposits position reflects accumulation from operating profit growth, with net income of 1,933.8 billion yen supporting internal cash generation. The balance sheet expansion of total assets by 6,331.8 billion yen year-over-year suggests active deployment of capital, potentially through business expansion, financial asset accumulation, or strategic investments. Equity increase of 3,722.9 billion yen indicates retained earnings accumulation contributing to capital base strengthening. The conservative equity ratio of 63.2% and limited interest burden coefficient of 1.055 suggest the company maintains adequate debt capacity and financial flexibility for future investment activities. Working capital management appears controlled given the moderate asset turnover, though detailed payables and receivables movements require cash flow statement verification. The dividend payout ratio of 41.8% implies approximately 58% of net income is retained for reinvestment or balance sheet strengthening, providing cushion for dividend sustainability.
Ordinary income of 2,621.9 billion yen compared to operating income of 2,484.5 billion yen indicates non-operating net contribution of approximately 137.4 billion yen, representing 0.6% of revenue. The interest burden coefficient of 1.055 confirms that non-operating items provided a net positive contribution to pre-tax profit, with financial income and equity method gains likely comprising the primary components. The tax burden coefficient of 0.738 results in effective tax rate of approximately 26.2%, within reasonable range for Japanese corporations. Operating margin expansion from 9.5% to 10.2% year-over-year demonstrates improved core business profitability independent of non-operating factors. The consistency between operating profit growth of 11.3% and bottom-line net income growth of 6.5% suggests stable earnings conversion, though the gap indicates some non-operating headwinds or increased tax burden. The ROIC of 4.7% remaining below target levels of 7-8% raises concerns about capital allocation efficiency and the sustainability of returns on deployed capital. Verification of operating cash flow exceeding net income would confirm cash-backed earnings quality.
Capital efficiency risk represents the most critical concern, with ROIC of 4.7% falling below target levels of 7-8% and potentially below the company's cost of capital, creating risk of value destruction if returns do not improve. Business portfolio concentration risk exists as the company's profitability improvement appears driven by product mix shifts toward higher-value segments such as medical and advanced materials, creating potential concentration exposure to specific markets or customer segments. Foreign exchange volatility poses ongoing risk given the company's global revenue composition, with currency fluctuations capable of materially impacting reported results and profitability.
[Industry Position] (Reference - Proprietary Analysis) Profitability: ROE 5.2% aligns with industry median 5.0% for FY2025 Q3, placing the company at the median of peer performance. Operating margin 10.2% exceeds industry median 8.3%, ranking in the upper half of manufacturing sector peers and confirming relative operational efficiency. Net profit margin 8.0% substantially exceeds industry median 6.3%, indicating strong bottom-line conversion. Financial Health: Equity ratio 63.2% approximates industry median 63.8%, reflecting typical financial conservatism within the manufacturing sector. Financial leverage 1.58x aligns closely with industry median 1.53x. Efficiency: Asset turnover 0.413 falls below industry median 0.58, suggesting lower capital intensity or room for improvement in asset utilization efficiency. ROIC 4.7% falls near the lower end of industry IQR range of 3-10%, confirming relative underperformance in capital efficiency. Growth: Revenue growth 4.4% exceeds industry median 2.7%, demonstrating above-average top-line momentum. (Industry: Manufacturing sector, N=98 companies, Comparison: FY2025 Q3 cross-sectional data, Source: Proprietary analysis)
Operating profitability improvement represents a key positive development, with operating margin expansion to 10.2% (exceeding industry median 8.3%) and operating income growth of 11.3% substantially outpacing revenue growth of 4.4%, suggesting successful execution of product mix optimization or cost management initiatives in higher-value business segments. Capital efficiency improvement emerges as the critical priority for sustainable value creation, as ROIC of 4.7% remains below target levels and trails asset turnover performance relative to industry peers (0.413 vs. industry median 0.58), indicating the company must enhance returns on deployed capital through improved asset utilization, disciplined capital allocation, or portfolio optimization. Financial stability and dividend sustainability appear well-supported by conservative capital structure with equity ratio of 63.2%, payout ratio of 41.8% providing comfortable coverage, and full-year guidance consistent with Q3 run-rate performance, though investors should monitor operating cash flow generation and free cash flow conversion to confirm cash-backed dividend capacity.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.